
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics Inc. demonstrated strong financial performance in the third quarter of 2025, with revenues reaching $136.1 million, surpassing consensus estimates and reflecting a significant 69% year-over-year growth along with a 14% quarter-over-quarter increase. The company's payer coverage showed improvement, increasing to 85%, which bodes well for its revenue sustainability as it continues to expand its market reach through effective contracts and ongoing clinical studies across its pipeline products. Overall, the projections indicate that revenue growth is expected to outpace operating costs, leading to improved operating margins and a potential cash flow positive position by 2026.
Bears say
Axsome Therapeutics Inc. is facing a negative outlook due to a downward revision of its full-year 2025 revenue forecast to $628.3 million, indicating potential challenges in achieving past projections. Key risks impacting its operations include concerns regarding market access for AUVELITY, setbacks in clinical trials for AXS-05 and other candidates, and the possibility of lower-than-expected commercial success attributed to competition and market penetration issues. Additionally, the company faces the potential for long-term dilution risks, which could further undermine investor confidence and financial stability.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares